DCGI
Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%
Wockhardt has expanded its marketing access for Miqnaf in India following the removal of a supply condition. The company's biotechnology sector recorded significant revenue growth, indicating strong demand for its products. Zaynich received US FDA approval for complicated urinary tract infections, serving as a milestone for Indian pharmaceuticals.
Court discharges former drug regulator S Eswara Reddy, three others in corruption case
The court found that the call recordings relied on by the prosecution did not attribute criminality to Reddy. None of the accused, it noted, had said in the recordings that Reddy demanded a bribe on any particular day or time to favour Bengaluru-based Biocon Biologics Ltd (BBL).
States urged to enforce ban on reuse of single-use medical devices
The Directorate General of Health Services has issued a directive to prohibit the reuse of single-use medical devices. Violations by some private hospitals have raised concerns regarding patient safety and regulatory compliance. The directive specifically targets misuse in high-stakes medical fields such as cardiology and neurosurgery. Monitoring and enforcement of compliance by healthcare establishments have been mandated.
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption
Dr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda injection were halted in July for technical evaluation. The new brands are manufactured by Hetero Labs, while distributors say the company may discontinue Obeda injectable supplies. Dr Reddy’s denies a replacement strategy.
From nasal delivery to sterile injectables: Biodeal Pharmaceuticals’ expansion plans
Biodeal Pharmaceuticals is set to broaden its horizons with a state-of-the-art sterile injectables plant in Himachal Pradesh. This venture will notably elevate its production capacities and diversify its contract development and manufacturing services. Biodeal is committed to fortifying existing partnerships with clients leveraging its innovative nasal and oral drug formulations.
Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancer
Dr Reddy's Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new indication allows treatment for adult patients with a combination of toripalimab, cisplatin, and paclitaxel. Approximately 80 percent of esophageal cancer cases in India are attributed to esophageal squamous cell carcinoma. The approval derives from positive results in the Phase 3 JUPITER-06 trial.
- Go To Page 1

National Formulary of India lists drugs not approved by CDSCO, DCGI seeks explanation from IPC
The National Formulary of India released its latest edition amidst concerns regarding unapproved drugs included in it. The Drug Controller General of India has communicated with the Indian Pharmacopoeia Commission regarding this discrepancy. Several drugs listed in NFI 2026 have not received approval from the Central Drugs Standard Control Organisation. Stakeholders have also raised complaints about the unavailability of the online version of NFI 2026.

Lupin launches fixed-dose triple combination inhaler for COPD in India
Lupin Ltd has launched Formoflo-G MDI, a new inhaler for chronic obstructive pulmonary disease management in India. This fixed-dose inhaler combines three therapies into a single device for better treatment outcomes. It aims to benefit over 55 million people living with COPD across the country. The Drug Controller General of India has approved this innovative product for use. Lupin is currently ranked second in the respiratory therapy segment in India.

QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell it
India's first approved dengue vaccine, QDENGA, will launch in the private market by mid-2027. Dr Reddy's Laboratories will distribute and promote the vaccine for individuals aged four to sixty. Takeda will retain rights for public market distribution as a future objective. QDENGA is a two-dose vaccine designed to protect against all four dengue virus serotypes. Dengue cases have significantly increased in India over the past two decades.

Dr. Reddy's launches nivolumab biosimilar in India
Dr Reddy's Laboratories has taken a significant step in cancer care with the introduction of NIVORZ, a biosimilar of nivolumab. Designed to enhance immune response against a variety of cancers, this new treatment has received approval from the DCGI for twelve specific indications. By making this intravenous therapy available, Dr Reddy's aims to broaden access to affordable, high-quality cancer care options for patients in need.

Export of drugs meant only for Indian market under DCGI lens
The DCGI has asked all port offices to ensure that products meant for the "India market only" are not exported after receiving complaints about the unauthorised export of drugs meant for the local market.

ET Impact: DCGI asks pharma cos to adhere to production quality standards
The DCGI's move comes a few days after ET reported that industrial excipients are used in manufacturing medicines and over 50 companies manufacturing cough syrups have failed quality tests. The World Health Organization (WHO) said in October last year that the deaths of dozens of children in Gambia from acute kidney injuries might be linked to contaminated cough and cold syrups made by an Indian drug manufacturer.

DCGI asks states to keep vigil on sale of falsified versions of 2 drugs following WHO alerts
The Drugs Controller General of India (DCGI) has issued an advisory to keep a strict watch on the sale and distribution of falsified versions of two drugs, Defitelio and Adcetris, following alerts from the World Health Organisation (WHO). The WHO has identified multiple falsified versions of Adcetris in circulation, and a falsified version of Defitelio has also been detected.

DCGI issues advisory as US-based Abbott recalls batches of Digene gel
Abbott India Limited, through a letter dated August 18, intimated to DCGI regarding voluntary product recall of all batches of Digene Gel of all flavours (mint, orange, mix fruits flavour) which are within the shelf life and manufactured at Goa facility. "The impugned product may be unsafe and its use may result in adverse reaction," the DCGI letter dated August 31 said.

All medicines to be sold under supervision of pharmacist, mandates DCGI
Newly-appointed DCGI Rajeev Singh Raghuvanshi has asked the state drug controllers to ensure that pharmacists should be physically present in the medical stores and that medicines must be sold under their direct supervision in retail pharmacies.

DCGI says medicines should be sold only under direct supervision of pharmacists in retail medical stores
"Ensure that pharmacists are physically present in the retail pharmacies/medical stores, and that medicines are sold/dispensed under their direct supervision. Ensure that no prescription medicine is sold/dispensed from the retail medicines shop without a proper and valid prescription," the DCGI said in the letter sent on March 9.

DCGI chief VG Somani gets three months extension
The extension period will come to effect from November 11. This is the second extension that Somani got. His term was set to end on August 14, 2022. In 2019, the government appointed Dr Somani as DCGI for a period of three years to head India’s apex drug regulatory agency Central Drugs Standard Control Organization (CDSCO).

Dr Reddy's gets DCGI nod for single-shot Sputnik Light vaccine
The standalone Sputnik Light vaccine is the latest jab to be approved by the DCGI as part of India's national inoculation effort against COVID-19. Sputnik Light is the second COVID-19 vaccine to be made available in India by Dr. Reddy's, reaffirming the company's commitment to explore every avenue in the fight against the pandemic, it said.

Bharat Biotech seeks full marketing approval from DCGI for its Covid vaccine Covaxin
In an application sent to the Drugs Controller General of India (DCGI) this week, V Krishna Mohan, Whole-Time Director at the Hyderabad-based company submitted complete information regarding chemistry, manufacturing and controls, along with pre-clinical and clinical data while seeking regular market authorisation for Covaxin.

Serum Institute gets DCGI's nod to manufacture Sputnik V in India for test, analysis
"The DCGI has granted permission to the Serum Institute to manufacture the Sputnik COVID-19 vaccine in India for examination, test and analysis at its licensed Hadapsar facility with certain conditions," an official source said.

Bharat Parenterals gets DCGI nod for favipiravir oral suspension
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.

AstraZeneca's Dapagliflozin tablets get DCGI nod for patients with chronic kidney disease
The company has "received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets 10 mg," AstraZeneca Pharma India said in a filing to BSE.

Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per vial
The DCGI has approved the company's remdesivir 100 mg per vial for restricted emergency use in India as part of the regulator's accelerated approval process to address urgent, unmet needs amid the evolving COVID-19 pandemic, Mylan said in a statement.

Glenmark Pharma shares jump nearly 9% on DCGI nod for clinical trials of Covid-19 tablets
The company said it is the first firm in India to receive such an approval from the DCGI.

DCGI to fast-track approval for Covid-19 drug, vaccine
The DCGI has offered seven measures for speeding up the process, from giving fast-track approval for repurposed drug to waiving animal study and offering flexible pathways which earlier would have taken months. It said applications from companies will be given “high priority” and that it will assist the companies in speeding up their research.

DCGI asks drug manufacturers to get clearance before August 30
The drug controller had earlier directed the state drug controllers to withdraw 294 FDCs which got licences without approval of DCGI.
Drug Regulator office has gone defunct as a quasi regulatory body takes charge of crucial approvals
Drug companies say that due to this committee, the DCGI has become non accountable to issues of drug approvals.
Pharma cos will require DCGI nod for exports
Domestic pharmaceutical companies will not be able to export medicines without the approval of central drug regulator Drug Controller General of India (DCGI) from next month, a health ministry official said.
DCGI’s plan on patent linkage gets HC booster
The Delhi High Court (HC) has directed the drug controller general of India (DCGI) not to give marketing or manufacturing permission to generic drugmakers for drugs that have already been granted patent in India.
Load More